Search results
Bulevirtide/Pegylated Interferon Combo Beats Monotherapy for Chronic Hepatitis D
MedPage Today· 7 days agoAt 24 weeks after the end of treatment, HDV RNA levels were undetectable in 46% of patients who...
Surrozen reports positive Phase 1a trial results for liver therapy By Investing.com
Investing.com· 2 days agoThe study, which involved healthy volunteers and patients with a history of liver cirrhosis, was...
‘Unusual’ cancers emerged after the pandemic. Doctors ask if covid is to blame.
Washington Post· 6 days agoKashyap Patel looked forward to his team’s Friday lunches. It was 2021, a year into the coronavirus...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoSZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide...
Morningstar· 6 days agoGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA - Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of...
Yucaipa News Mirror· 5 days agoBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that new data supporting the long-term safety and efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) will be presented at the ...
'I spent 40 days and 40 nights in isolation, then went on to claim medals' - cycling is a daily...
Cycling Weekly· 1 day agoWhen I catch up with Nicholas Topley in early 2024, he has just returned from a ride. Battling...
Paxlovid Fails First Test in Long COVID
MedPage Today· 6 days agoThe study was also presented at the Demystifying Long COVID North American Conference in Boston. "I don't think we've shown that Paxlovid...
Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID
Medical Xpress· 5 days agoIn a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day...